P0573 Effectiveness and safety of mirikizumab in patients with moderate-to-severe ulcerative colitis: a real-life multicenter study

作者
Ferdinando D’Amico,Fabrizio Fanizzi,Arianna Dal Buono,O M Nardone,Giorgia Michela Lauriola,Alessandra Zilli,Mariangela Allocca,Laurent Peyrin‐Biroulet,Gionata Fiorino,F Castiglione,L Massimino,Mauro Mastronardi,Alessandro Armuzzi,Silvio Danese
出处
期刊:Journal of Crohn's and Colitis [Oxford University Press]
卷期号:20 (Supplement_1)
标识
DOI:10.1093/ecco-jcc/jjaf231.754
摘要

Abstract Background Mirikizumab is a monoclonal antibody directed against the p19 subunit of interleukin (IL)-23 approved for the management of patients with moderate-to-severe ulcerative colitis (UC). This study aims to evaluate the effectiveness and safety of mirikizumab in real-life setting. Methods This was a retrospective multicenter cohort study including adult patients with diagnosis of UC treated with mirikizumab. Patients were enrolled in 5 third-level Italian centers from June 2024 to August 2025. All patients with at least 3 months of follow-up after therapy initiation were eligible. The primary outcome was the clinical remission rate (defined as partial Mayo Score (pMS) < 2 with a rectal bleeding subscore of 0) at week 12 (w12) and 24 (w24). Secondary outcomes included intestinal ultrasound (IUS) remission (defined as MUC ≤ 6.2), changes in mayo endoscopic score (MES), bowel urgency (BU, measured by the Numeric Rating Scale (NRS) urgency score), fecal calprotectin (FC) levels up to w24 and safety profile of mirikizumab. Results A total of 236 patients were included (60.2% male; median age 47.8 ± 18.1 years). Most (77.5%) had prior exposure to ≥ 1 advanced therapy (including 62 patients treated with ustekinumab), and 14.8% had received ≥4 agents before mirikizumab. Mirikizumab induced a significant reduction in pMS at w12 (p = 1.42 × 10−¹9; r = 0.83; n = 210) and w24 (p = 4.11 × 10−²¹; r = 0.89; n = 179). Steroid-free clinical remission at w12 was achieved by 46.6% of patients. MES improved significantly at w12 (p = 3.89 × 10−³; r = 0.68; n = 38) and w24 (p = 2.39 × 10−¹¹; r = 0.90; n = 85). IUS remission was not significant at w12 (p = 0.17; n = 151) but increased by w24 (p = 1.69 × 10−5; V = 0.35; n = 142). BU improved significantly at w12 (p = 4.05 × 10−¹¹; r = 0.73; n = 174) and w24 (p = 1.08 × 10−10; r = 0.78; n = 132). FC reductions were significant at both w12 (p = 4.31 × 10−¹¹; r = 0.57; n = 182) and w24 (p = 5.34 × 10−8; r = 0.52; n = 147). Extended induction was required in 59.3% of patients at w12, and 3.4% underwent intravenous re-induction at w24. Mirikizumab was discontinued in 11 patients by w12 and 16 by w24, mainly due to treatment failure (one allergic reaction). Adverse events (AEs) were uncommon (6 at w12; 3 at w24), including upper respiratory tract infection, cytomegalovirus ( CMV ) infection, herpes zoster, infusion reaction, rash, pyrexia, and arthralgia. No serious AEs were recorded. No clinically relevant liver enzyme changes were observed. Conclusion In this real-world UC cohort, mirikizumab demonstrated robust and durable effectiveness across clinical, endoscopic, biochemical, and IUS outcomes, with low discontinuation rates, and no serious safety signals through 24 weeks. Conflict of interest: Dr. D’Amico, Ferdinando: Grant: ECCO fellowship grant 2020 ECCO grant 2021 Personal Fees: F D’Amico has served as a speaker for Abbvie, Alfasigma, Ferring, Lilly, Sandoz, Janssen, Fresenius Kabi, Galapagos, Giuliani, MSD, Pfizer, Takeda, Tillotts, and Omega Pharma he also served as an advisory board member for Abbvie, AnaptysBio, Ferring, Fresenius Kabi, Galapagos, Janssen, Lilly, MSD, Takeda, and Nestlè. Fanizzi, Fabrizio: No conflict of interest Dal Buono, Arianna: speaker’s fees from AbbVie, Alphasigma, Ferring, Lilly, Janssen, and Celltrion Nardone, Olga Maria: Advisory board fees from Eli Lilly, Nestlè, Janssen Speaker fees from AbbVie, Janssen, Eli Lilly, Ferring, Alfa Sigma, Recordati, Noòs, and Pfizer Lauriola, Giorgia Michela: No conflict of interest Zilli, Alessandra: Personal Fees: Speaking and consulting fees from Tillotts, Galapagos, Abbvie, Takeda, Janssen, Alfasigma, Sandoz, Lilly, Pfizer Allocca, Mariangela: Personal Fees: consulting fees from Nikkiso Europe, Mundipharma, Janssen, Abbvie, Pfizer, Ferring, Galapagos, Sandoz, Lilly and Alfasigma Peyrin-Biroulet, Laurent: CONSULTING Abbvie, Abivax, Adacyte, Alimentiv, Alfasigma, Amgen, Apini, Banook, BMS, Celltrion, Enthera, Ferring, Fresenius Kabi, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, LifeMine, Medac, Morphic, MSD, Nordic Pharma, Novartis, Oncodesign Precision Medicine, ONO Pharma, OSE Immunotherapeuthics, Par’ Immune, Pfizer, Prometheus, Roche, Roivant, Samsung, Sandoz, Sanofi, Sorriso, Spyre, Takeda, Teva, ThirtyfiveBio, Tillots, Vectivbio, Vedanta, Ventyx. LECTURE Abbvie, Alfasigma, Amgen, Biogen, Celltrion, Ferring, Galapagos, Genentech, Gilead, Iterative Health, Janssen, Lilly, Medac, MSD, Nordic Pharma, Pfizer, Sandoz, Takeda, Tillots Fiorino, Gionata: Personal Fees: Takeda, Johnson & Johnson, Alfasigma, AbbVie, Celltrion, Pfizer, Sandoz, Abivax, Lilly, STADA Castiglione, Fabiana: Honoraria from: Takeda, AbbVie, Celltrion, Johnsson Johnsson, Cadigroup, Sandoz, Pfizer, Lilly, Lionhealth, Nestlè Massimino, Luca: No conflict of interest Mastronardi, Mauro: none Armuzzi, Alessandro: Consulting fees from AbbVie, Abivax, Alfa Sigma, Astra Zeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Enthera, Ferring, Galapagos, Gilead, Giuliani, Janssen, Lionhealth, MSD, Nestlé, Pfizer, Protagonist Therapeutics, Roche, Samsung Bioepis, Sanofi, Sandoz, Takeda, Teva Pharmaceuticals, Tillots Pharma Speaker’s fees from AbbVie, Abivax, AG Pharma, Alfa Sigma, Biogen, Bristol-Myers Squibb, Celltrion, Eli-Lilly, Ferring, Galapagos, Gilead, Janssen, Lionhealth, MSD, Novartis, Pfizer, Roche, Samsung Bioepis, Sandoz, Takeda, Teva Pharmaceuticals Research support from Biogen, MSD, Takeda, and Pfizer Non-financial support from Abbvie, Janssen, MSD, Pfizer, Takeda Danese, Silvio: Personal Fees: AbbVie, Alimentiv, Allergan, Amgen, Applied Molecular Transport, AstraZeneca, Athos Therapeutics, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Celltrion, Dr Falk Pharma, Eli Lilly, Enthera, Ferring Pharmaceuticals Inc., Gilead, Hospira, Inotrem, Janssen, Johnson & Johnson, Morphic, MSD, Mundipharma, Mylan, Pfizer, Roche, Sandoz, Sublimity Therapeutics, Takeda, Teladoc Health, TiGenix, UCB Inc., Vial, Vifor Lecture fees from Abbvie, Amgen, Ferring Pharmaceuticals Inc., Gilead, Janssen, Mylan, Pfizer, Takeda

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
耗子完成签到,获得积分10
1秒前
白白白发布了新的文献求助10
1秒前
迷路鞋子完成签到,获得积分10
1秒前
川哥完成签到,获得积分10
1秒前
勤劳的孤云完成签到,获得积分10
1秒前
撇弃途上完成签到,获得积分10
2秒前
2秒前
你倒是发啊完成签到,获得积分10
2秒前
科研狗完成签到,获得积分10
2秒前
2秒前
sxlixin12的应助被布朗尼妮采纳,获得10
2秒前
张毛毛完成签到,获得积分10
2秒前
Yang完成签到 ,获得积分10
2秒前
工作热情仔完成签到,获得积分0
4秒前
文艺天奇完成签到,获得积分10
4秒前
Qizhang发布了新的文献求助10
5秒前
5秒前
singyu9完成签到,获得积分10
5秒前
Cathy完成签到,获得积分10
5秒前
内向鸣凤完成签到,获得积分10
5秒前
小慈完成签到,获得积分10
5秒前
5秒前
楚阳完成签到,获得积分10
6秒前
皮卡第的玫瑰完成签到,获得积分10
6秒前
念兹在兹完成签到,获得积分10
6秒前
数星星的薯片完成签到,获得积分10
6秒前
缓慢初雪完成签到 ,获得积分10
7秒前
xiaoqiao发布了新的文献求助30
7秒前
123PY完成签到,获得积分10
7秒前
7秒前
7秒前
8秒前
yiyi完成签到,获得积分10
8秒前
8秒前
MMM完成签到,获得积分10
9秒前
为人朴素的小马完成签到,获得积分10
10秒前
上官若男的应助被吴锋采纳,获得10
10秒前
沈晨完成签到,获得积分10
11秒前
xxxrisjune完成签到,获得积分10
11秒前
高兴象完成签到,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180135
求助须知:如何正确求助?哪些是违规求助? 9570290
关于积分的说明 21809391
捐赠科研通 7776237
什么是DOI,文献DOI怎么找? 3433266
关于科研通互助平台的介绍 2557465
邀请新用户注册赠送积分活动 2479039